Download our research report excerpt to learn how the U.S. “health technology assessment” (HTA) landscape is evolving and what you can do as a medical leader to respond.
More from the Medical Affairs Leadership Council
ICER 101: How the 'drug pricing watchdog' is changing how we perceive value
Given the advent of new seven-figure drugs and perpetual debates about medical value, it’s not surprising to see ICER in the news on a weekly basis. But what does the organization actually do? Advisory Board offers a primer on ICER, explain its rising influence, and uncover how its debate with biopharma is affecting conversations around value.
Learn more about our research
We provide research and events to equip life sciences medical leaders with actionable customer insights that catalyze more compelling, impactful medical value narratives. We empower progressive medical affairs executives through our member-driven research initiatives that help you: (1) understand how customers make decisions, (2) optimize sources and uses of medical evidence, and (3) drive more productive conversations around value. Learn more about our research and membership features.
Upcoming event: EyeForPharma20
Each year, our Advisory Board research experts are invited to speak at industry conferences across the country. At EyeForPharma19, we delivered a standing-room only presentation, “How Payers and IDNs Think About Value and the Data They Trust to Make Decisions.” This presentation was so popular, we’re heading back to EyeForPharma20 to present our latest research. Learn more.